Selinisol vs. pomalidomide: A comparison of two major drugs for the treatment of multiple myeloma

Selinexor (Selinexor) and Pomalidomide (Pomalidomide) are both important drugs in the treatment of multiple myeloma, but they have their own characteristics in terms of mechanism of action, indications, side effects and combination treatment options.

1. Mechanism of action:

Selinisol: As a selective nuclear transport inhibitor, it blocks the transport process of specific proteins in the nucleus and interferes with key signaling pathways within cancer cells, thereby effectively inhibiting the growth and proliferation of tumor cells.

Pomalidomide: It is an immunomodulatory drug that treats multiple myeloma by activating the patient's own immune system, enhancing the ability to recognize and attack tumor cells, and directly inhibiting the growth of tumor cells.

2. Indications and usage scenarios:

Selinisol: Mainly used to treat patients with multiple myeloma who have failed to respond to or are intolerant to other treatments. It can be used as monotherapy or in combination with drugs such as dexamethasone or bortezomib to enhance the effectiveness of treatment.

Pomalidomide: is mainly used for patients with relapsed or refractory multiple myeloma after at least two previous treatment regimens. It is often used in combination with drugs such as lenalidomide to provide a more comprehensive treatment strategy.

3. Side effects:

Selinisol: Common side effects include nausea, vomiting, fatigue, and digestive symptoms such as loss of appetite. In addition, it may cause blood-related side effects such as thrombocytopenia and anemia.

Pomalidomide: Common side effects also include anemia, fatigue, nausea, and vomiting. But in addition, it may increase the risk of deep vein thrombosis, infection, and skin reactions.

4. Combined treatment plan:

Selinesol-based combination therapy in relapse/has demonstrated significant efficacy in refractory multiple myeloma. Studies have shown that in patients with relapsed or refractory multiple myeloma, the treatment regimen of seliniso combined with pomalidomide and dexamethasone can achieve an objective response rate of up to 65% and a median progression-free survival of 10.9 months. The objective response rate of another regimen, XPD-40, was 48.1%, which also showed a certain therapeutic effect.

In summary, selinesol and pomalidomide each have their own advantages in the treatment of multiple myeloma. Doctors should choose appropriate drugs and treatment options based on the patient's specific illness and physical condition.